XASX
UCM
Market cap2mUSD
Sep 23, Last price
0.01AUD
Name
Uscom Ltd
Chart & Performance
P/E
—
P/S
1.21
EPS
—
Div Yield, %
—
Shrs. gr., 5y
4.81%
Rev. gr., 5y
-5.82%
Revenues
3m
-30.80%
Net income
-3m
L+59.19%
CFO
-3m
L+132.94%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Globally, Uscom Limited specializes in the creation, production, and distribution of non-intrusive medical instruments for assessing heart and lung health. Its product portfolio includes the USCOM 1A, a device utilizing Doppler ultrasound to non-invasively assess hemodynamic and cardiovascular performance. Also available is the BP+, a central blood pressure monitor employing supra-systolic oscillometry to gauge blood pressure and its waveforms both centrally (at the heart) and peripherally (in the arm). The company also produces the SpiroSonic, an ultrasound-based multi-path system for evaluating pulmonary function. Further expanding its offerings, Uscom presents the SpiroSonic AIR, a digital multipath ultrasonic spirometer featuring an integrated viral disinfection system capable of neutralizing pathogens like COVID and tuberculosis, alongside other respiratory equipment. Uscom's solutions are delivered to hospitals and various healthcare facilities via a broad network of distribution alliances. Established in 1999, the firm initially operated as Uscom Pty Limited before adopting the name Uscom Limited in October 2003. Its main corporate office is situated in Sydney, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||